Introduction {#H1-1-ZOI200191}
============

In the standard Medicare Part D benefit design, the coverage gap (ie, "donut hole") has traditionally exposed patients to high out-of-pocket costs, which have been associated with cost-related medication nonadherence and unpredictable annual drug expenses.^[@zoi200191r1],[@zoi200191r2],[@zoi200191r3]^ From 2006 through 2010, patients were responsible for 100% of drug costs while in the gap. In 2010, this situation required patients who reached the gap to spend \$3610 out of pocket before moving into the catastrophic phase of the benefit (in which spending decreased from 100% to 5% of the drug's list price). The landmark 2010 Patient Protection and Affordable Care Act (ACA) represented an overhaul of the US health care system and included a decade-long plan to close the coverage gap by introducing yearly reductions in patient out-of-pocket cost in the gap phase.^[@zoi200191r4]^ These reductions were offset by requiring manufacturers to pay a 50% discount on brand-name drugs beginning in 2011 and by gradually increasing plan contributions (from 0% in 2011 to 25% in 2020). The Bipartisan Budget Act of 2018 increased manufacturer discounts from 50% to 70% and reduced plan payments to 5% for branded drugs filled in the coverage gap in 2019.^[@zoi200191r5]^ With these changes, by 2019, Medicare Part D beneficiaries pay 25% of a brand-name drug's list price in the coverage gap. Early research has found that in its first few years of implementation, the ACA was associated with decreased overall out-of-pocket spending on prescription drugs and that this association was most pronounced for those patients who enter the coverage gap.^[@zoi200191r1],[@zoi200191r6]^

Despite improved financial protections for some patients, those with high drug spending remain at significant financial risk. Although their cost sharing in the gap has decreased since 2010, patients have remained responsible for 5% of the list price of filled drugs after they reach the out-of-pocket gap-phase threshold and enter the catastrophic phase of coverage. Over time, the number of patients reaching the catastrophic phase of the benefit has increased, as has their out-of-pocket spending.^[@zoi200191r7]^ This situation has been associated with yearly increases in drug prices and the continued introduction of new and higher-cost specialty drugs over time.^[@zoi200191r8],[@zoi200191r9],[@zoi200191r10],[@zoi200191r11]^

For patients, these expensive specialty drugs can represent a substantial ongoing financial liability because there is no limit on patient out-of-pocket spending in the catastrophic phase. In addition to financial hardships, increased cost exposure has important clinical implications associated with delayed initiation of treatment as well as higher rates of prescription abandonment.^[@zoi200191r12],[@zoi200191r13]^ Prior work^[@zoi200191r14]^ has found that price increases have erased anticipated savings for Medicare beneficiaries using anticancer treatments, but whether this phenomenon exists in other specialty drug markets is unclear.

Rheumatoid arthritis (RA) represents one of the largest markets for expensive specialty drugs^[@zoi200191r15]^; moreover, patients with RA tend to take specialty medications for long periods because their disease is typically not life-shortening and requires consistent biologic therapy to remain controlled. For such patients, there remains a question regarding the effectiveness of the ACA's changes to Medicare Part D standard benefit designs in limiting these patients' annual out-of-pocket costs. Our objectives were to estimate expected out-of-pocket spending for Part D enrollees using biologic therapy for RA before and after the coverage gap closed, comparing 2010 data with 2019 data.

Methods {#H1-2-ZOI200191}
=======

This cross-sectional study used the Centers for Medicare & Medicaid Services Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information files quarterly data set for 2010 through 2019. This study was deemed exempt from review by the Vanderbilt University School of Medicine Institutional Review Board. Informed consent was waived because this research did not involve human participants. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](https://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.

The unit of observation was the Medicare Part D plan-year for each drug rather than individual beneficiary-level data. Quarter 1 (January 1 to March 31) data were used to reflect benefit designs for the entire year. To identify the drugs of interest, we conducted a literature search of the biologic medications currently approved and recommended to treat RA and that were primarily reimbursed through Part D (outpatient drug benefit).^[@zoi200191r16],[@zoi200191r17]^ We limited the study to biologic medications because the analysis of interest centers on specialty drugs (which include biologics with high list prices). Included drugs were required to have entered the market by 2018 to allow comparison across years. National Drug Codes (NDCs) corresponding to a form of a drug expressly marketed for another indication (ie, Humira Crohn's Disease Starter Pack) were excluded from our analysis because physicians are unlikely to prescribe these specific products for the treatment of RA (eTable 1 in the [Supplement](#note-ZOI200191-1-s){ref-type="supplementary-material"} gives detailed information on product exclusions).

Statistical Analysis {#H2-1-ZOI200191}
--------------------

We calculated the median point-of-sale price per fill (typically representing a 30-day supply) for each drug in 2010 (or the year of market entry) through 2019, adjusted for medical inflation. Next, we examined coverage rates for each drug, defined as the percentage of formularies with the drug available and the percentage of these formularies that used a coinsurance (vs co-payments) for setting patient cost sharing and the median coinsurance used. When prescribing information indicated that 2 doses or forms of a drug were equivalent therapy choices, we also calculated coverage for that drug for all strengths and routes of administration. Next, we calculated annual projected out-of-pocket spending using the median coinsurance and the median point-of-sale price per fill, assuming patients fill 12 prescriptions per year and no other medications. All annual out-of-pocket spending was also inflation adjusted to 2019 dollars. For NDCs that corresponded to a quantity limit greater or less than the usual number of doses per month, we applied a multiplier to standardize costs for an expected 12 prescriptions. A complete list of the NDCs included and multipliers used is given in eTable 2 in the [Supplement](#note-ZOI200191-1-s){ref-type="supplementary-material"}. Finally, we estimated costs by benefit phase for patients filling prescriptions in 2010 and those filling the same prescriptions in each year from 2011 through 2019 to determine how out-of-pocket spending changed overall and by coverage phase over time. In 2010, \$250 was subtracted from the total out-of-pocket cost for the year to reflect the 1-time \$250 check received by beneficiaries who reached the coverage gap as mandated by the ACA. Analyses were completed using Stata software, version 16.0.801 (StataCorp).

Results {#H1-3-ZOI200191}
=======

We investigated 17 drug and strength combinations. [Table 1](#zoi200191t1){ref-type="table"} lists the overview characteristics of the key drugs of interest. For all drugs studied, most plans used a coinsurance cost-sharing model in the initial coverage phase. After adjusting all prices to 2019 US dollars, the median price per fill increased for all drugs studied. Prices increased by more than 20% for every drug that had been on the market for more than 5 years, with the exception of the 100-mg/1-mL golimumab autoinjector, which entered the market in 2015 at a higher price than its existing formulation (\$3867 vs \$3306 for the 50-mg/0.5-mL golimumab autoinjector). The largest price increase was for the 20-mg/0.4-mL formulation of adalimumab, which increased from \$1894 per fill in 2010 to \$5299 per fill in 2019. For the 6 products on the market since 2010, the median list price increased a mean (SD) of 160% (17%; range, 136%-180%) by 2019.

###### Baseline Characteristics and Median List Price, Percentage of Coverage, and Coinsurance Information for Drugs of Interest

  Product                      First available year (2010-2019)   Median list price per fill, \$[^a^](#zoi200191t1n1){ref-type="table-fn"}   Coverage, %                     
  ---------------------------- ---------------------------------- -------------------------------------------------------------------------- ------------- ----- ----- ----- -----
  Tocilizumab, 162 mg/0.9 mL   2015                               796                                                                        1002          37    37    98    100
  Certolizumab pegol                                                                                                                                                         
  200 mg                       2010                               1795                                                                       4400          67    26    98    100
  200 mg/1 mL                  2011                               1885                                                                       4343          64    26    97    100
  Etanercept                                                                                                                                                                 
  25 mg                        2010                               1007                                                                       2628          85    73    98    100
  50 mg/1 mL                   2010                               2019                                                                       5253          85    73    98    100
  Adalimumab                                                                                                                                                                 
  10 mg/0.2 mL                 2016                               4216                                                                       5309          99    100   100   100
  20 mg/0.4 mL                 2010                               1895                                                                       5300          45    100   98    100
  40 mg/0.8 mL                 2010                               1890                                                                       5254          100   100   98    100
  Sarilumab                                                                                                                                                                  
  150 mg/1.14 mL               2018                               3157                                                                       3385          7     30    100   100
  200 mg/1.14 mL               2018                               3157                                                                       3385          7     30    100   100
  Abatacept                                                                                                                                                                  
  125 mg/1 mL                  2012                               2307                                                                       4347          52    39    99    100
  50 mg/0.4 mL                 2018                               4359                                                                       4442          42    39    100   100
  87.5 mg/0.7 mL               2018                               4359                                                                       4442          42    39    100   100
  Golimumab                                                                                                                                                                  
  100 mg/1 mL                  2015                               3867                                                                       5658          50    30    100   100
  50 mg/0.5 mL                 2010                               2065                                                                       4873          51    30    98    100
  Tofacitinib                                                                                                                                                                
  5 mg                         2014                               2510                                                                       4528          39    66    100   100
  Extended-release 11 mg       2017                               4101                                                                       4536          60    62    100   100

All prices were inflation adjusted and are reported in 2019 dollars.

For these same 6 drugs, [Figure 1](#zoi200191f1){ref-type="fig"} shows the annual out-of-pocket amount spent per year averaged across all products, segmented by dollars spent in each phase of coverage. For the products available from 2010 through 2019, mean (SD) annual out-of-pocket spending decreased from \$6108 (\$234; (range, \$5647-6282; \$5858 after the 1-time \$250 rebate) in 2010 to \$4801 (\$620; range, \$3594-\$5196) in 2019. However, these savings were largely attributable to the mandatory manufacturer 50% rebate for brand-name drugs filled in the coverage gap, which reduced patients' cost exposure from 100% to 50% between 2010 and 2011. Despite continued reductions in required patient cost sharing as the coverage gap closed over time, there was a mean (SD) 19% (9%; range, 2%-26%) increase in the mean annual out-of-pocket cost from 2011 to 2019 (from \$4026 to \$4801). There was a slight decrease in estimated annual out-of-pocket spending from 2018 to 2019 as the Bipartisan Budget Act accelerated the closing of the coverage gap. This expedited closure resulted in a 10% decrease in gap cost exposure between 2018 and 2019 (vs the 2.5% and 5% decreases in the previous 8 years) and a 20% increase in manufacturer discount in the gap, which did not affect patient out-of-pocket costs directly but rather propelled patients into the catastrophic phase more quickly. As expected, gap spending decreased a mean (SD) of 46% (2%; range, 45%-50%) and catastrophic spending increased a mean (SD) of 38% (5%; range, 29%-41%) for the 6 products on the market from 2010 through 2019. [Figure 2](#zoi200191f2){ref-type="fig"} shows the out-of-pocket spending in 2010 vs 2019 for these products.

![Mean Annual Out-of-Pocket Expenses Across All Products Available in 2010 to 2019 by Phase of Spending\
The 6 products available from 2010 through 2019 included in this mean analysis were 200 mg of certolizumab pegol, 25 mg of etanercept, 50 mg of etanercept, 20 mg/0.4 mL of adalimumab, 40 mg/0.8 mL of adalimumab, and 50 mg/0.5 mL of golimumab. Note that the annual out-of-pocket cost in 2010 does not reflect the 1-time \$250 check given to patients who reached the gap in that year.](jamanetwopen-3-e203969-g001){#zoi200191f1}

![Annual Out-of-Pocket Expenses in 2010 vs 2019 by Phase of Spending for Products Entering the Market Before 2010](jamanetwopen-3-e203969-g002){#zoi200191f2}

For 13 of the 17 drug-strength combinations covered by Part D during the study period, expected annual out-of-pocket cost was lower in 2019 than in the first year the product was available ([Table 2](#zoi200191t2){ref-type="table"}). Expected out-of-pocket spending was higher in 2019 for 4 of the 5 products entering the market from 2011 to 2015: 200 mg/1 mL of certolizumab pegol, 125 mg/mL of abatacept, 100 mg/1 mL of golimumab, and 5 mg of tofacitinib. For all 17 drugs, projected annual out-of-pocket cost was a mean (SD) of \$4613 (\$698; range, \$2618-\$5439) in 2019; the overall cost of tocilizumab was the lowest at \$2618, and the next lowest was 25 g of etanercept at \$3594. The 100-mg/1-mL dose of golimumab was the most expensive at a projected annual cost of \$5439. Catastrophic spending increased a mean (SD) of 13% (14%) for products entering after 2010 and a mean (SD) of 8% (3%) for products entering after 2015.

###### Projected Annual Out-of-Pocket Expenses in First Available Year vs 2019

  Product                               First available year (2010-2019)   Projected annual out-of-pocket cost, \$   Change in annual out-of-pocket costs from first available year to 2019, \$   
  ------------------------------------- ---------------------------------- ----------------------------------------- ---------------------------------------------------------------------------- -------
  Certolizumab pegol, 200 mg            2010                               6108                                      4710                                                                         −1398
  Etanercept                                                                                                                                                                                      
  25 mg                                 2010                               5647                                      3593                                                                         −2054
  50 mg/1 mL                            2010                               6254                                      5168                                                                         −1086
  Adalimumab                                                                                                                                                                                      
  20 mg/0.4 mL                          2010                               6177                                      5196                                                                         −981
  40 mg/0.8 mL                          2010                               6177                                      5168                                                                         −1009
  Golimumab, 50 mg/0.5 mL               2010                               6282                                      4967                                                                         −1315
  Certolizumab pegol, 200 mg/1 mL       2011                               4046                                      4676                                                                         630
  Abatacept, 125 mg/1 mL                2012                               4317                                      4625                                                                         308
  Tofacitinib, 5 mg                     2014                               4218                                      4787                                                                         569
  Tocilizumab, 162 mg/0.9 mL            2015                               3225                                      2618                                                                         −607
  Golimumab, 100 mg/1 mL                2015                               5067                                      5439                                                                         372
  Adalimumab, 10 mg/0.2 mL              2016                               5290                                      5202                                                                         −88
  Tofacitinib, extended-release 11 mg   2017                               5025                                      4765                                                                         −260
  Sarilumab                                                                                                                                                                                       
  150 mg/1.14 mL                        2018                               4524                                      4075                                                                         −449
  200 mg/1.14 mL                        2018                               4524                                      4075                                                                         −449
  Abatacept                                                                                                                                                                                       
  50 mg/0.4 mL                          2018                               5179                                      4682                                                                         −497
  87.5 mg/0.7 mL                        2018                               5179                                      4682                                                                         −497

Discussion {#H1-4-ZOI200191}
==========

On average, annual out-of-pocket costs for patients taking specialty biologics for RA decreased from 2010 to 2019 as the coverage gap was closed, and for 14 of the 17 drugs studied, patients paid a lower annual out-of-pocket cost in 2019 than in 2010 or the year first available. However, these decreases were associated with a 50% decrease in gap cost exposure from 2010 to 2011, a large 1-time decrease masking underlying trends in the 9 years since. The nearly 20% increase in projected annual out-of-pocket cost from 2011 through 2019 for the 6 available products suggests that the small annual decreases (2.5%-10%) in patient cost exposure in the gap from 2011 through 2019 have not been sufficient to keep pace with yearly increases in list prices as well as the introduction of increasingly expensive drugs. Without the large decrease in patient coverage gap cost sharing from 2010 to 2011, the data from the past decade revealed that 4 of the 5 drugs entering the market between 2011 and 2015 had higher annual out-of-pocket costs in 2019 than in their year of entry. Of importance, these products became available after the 2010 to 2011 coverage gap change but have also been on the market for at least 5 years, which is long enough for the compounded associations of annual increases in list prices with further reductions in gap cost sharing. The sole exception to this trend was tocilizumab, which was also the lowest-cost product at \$3225 in 2015 and \$2618 in 2019. The lower price of tocilizumab was likely attributable to its mechanism of action as an interleukin inhibitor because current practice guidelines recommend a different drug class, a tumor necrosis factor inhibitor, as first-line biologic therapy.^[@zoi200191r16]^

Although patients paid less in 2019 than they did in 2010, the question remains whether a decrease from \$5858 in 2010 (after the \$250 rebate check) to \$4801 in 2019 accomplished the ACA's goal of significantly easing the burden of prescription drug costs, especially as upward price trends in recent years have edged patients even closer to their out-of-pocket costs a decade ago. These prices continue to represent a substantial cost burden for older patients with RA and have important clinical implications. For Medicare patients, having RA is associated with a 3-fold increase in risk of cost-related treatment nonadherence,^[@zoi200191r18]^ with research showing that patients with RA with the highest levels of cost exposure are almost 30 times more likely to abandon their initial prescription.^[@zoi200191r19]^ In addition, the proportion of patient spending that occurs in the catastrophic phase has increased each year. Now that the coverage gap has been officially closed, annual increases in list prices of these drugs may further increase catastrophic-phase spending. The positive association between length of time on the market and mean increase in catastrophic spending, including a 38% increase for products available in 2010, 13% increase for products entering after 2010, and 8% increase for products entering after 2015, supports the possibility of continued growth in catastrophic phase spending. Given the current lack of an out-of-pocket maximum on Medicare Part D, this finding of increasing catastrophic spending can represent an enormous financial liability for patients. Finally, it is not uncommon for patients to switch between biologics because of inadequate clinical response or adverse events, with 1 study^[@zoi200191r20]^ of Medicare patients estimating an approximately 10% switch rate in the first year of therapy alone. In contrast to the treatment algorithms available for many common diseases, the trial-and-error approach often used for patients with RA in whom the first choice biologic fails may be associated with an increased likelihood of patients being switched to new and more costly drugs because there is no guideline for sequential biologic treatments.

Limitations {#H2-2-ZOI200191}
-----------

This study has limitations. It is limited by the use of list prices, which fail to capture the rebates that may reduce prices paid by Medicare Part D plans for drugs filled. However, patient out-of-pocket spending is based on list prices rather than net prices, limiting the effect on our analysis.^[@zoi200191r21]^ To allow for year-to-year comparisons, we focused on the annual expense associated with a single biologic filled every month, ignoring other treatments filled under Medicare Part D. Most patients receive several other medications as well, which would result in our underestimating out-of-pocket spending by patients. In addition, this analysis focused on beneficiaries who did not qualify for a low-income subsidy because their cost sharing was fixed and would change only slightly during the study period.^[@zoi200191r22]^ However, for the more than two-thirds of Medicare Part D patients who do not qualify for such assistance, there was a trend in increasing cost exposure during the last 9 years, and there is no longer a yearly decrease in patient cost sharing in the gap. Although not all patients with RA initiate biologic therapy, estimates for biologic therapy initiation in the first few years after diagnosis range from 20% to 40%.^[@zoi200191r23],[@zoi200191r24]^ However, there has been a recent push toward earlier use of biologics to capitalize on a window of opportunity early in the disease course,^[@zoi200191r25]^ suggesting that the percentage of patients with RA affected by high biologic costs will continue to increase. Of note, the patients with the highest disease burden will be most exposed to these costs.

In addition, it is possible that the continuing development of the RA biosimilar market will increase price competition for these therapies and make available additional treatment options at a lower cost. However, meaningful cost reduction from biosimilars is currently limited by aggressive litigation by the biologic manufacturers and an insufficient number of competitors to markedly affect price.^[@zoi200191r26]^ In addition, a 2019 survey of US rheumatologists found that practitioners are hesitant to switch a patient with stable RA from a biologic to its biosimilar, indicating a substantial first-mover advantage for the biologics; that is, the shift from biologic to biosimilar may be more gradual if primarily occurring in biologic-naive patients with newly diagnosed RA.^[@zoi200191r27]^

Conclusions {#H1-5-ZOI200191}
===========

The mean projected annual out-of-pocket cost for an RA biologic was lower in 2019 than in 2010 or year of first entry, and the closure of the coverage gap was associated with a benefit to consumers overall. However, from 2011 to 2018, mean annual cost exposure for an RA biologic increased over inflation every year, even with the benefit of yearly reductions in gap cost exposure. As the coverage gap is now considered closed, our results suggest a need for out-of-pocket maximums in the catastrophic phase to limit older Americans' yearly financial burden and allow them to better estimate their annual drug costs. In the interim, however, limiting the allowed annual increase in list prices and capping out-of-pocket costs for Medicare Part D enrollees may be associated with decreased financial burden for patients receiving biologic therapies.
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